Applications

1453 – PD-L1 testing for access to pembrolizumab in patients with unresectable mesothelioma

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status Pre-assessment
  • Type -
  • Pre-PASC consultation -
  • Pre-MSAC consultation -
  • Outcome -

Application details

Reason for application

New MBS item.

Service or technology in this application

ImmunoHistoChemistry (IHC) test for evaluation of Programmed Cell Death Ligand 1 (PD-L1) expression to determine eligibility for treatment with pembrolizumab.

Type: Co-dependent technology

Medical condition this application addresses

Unresectable mesothelioma.

Meetings to consider this application

  • PASC meeting: 8 December 2016
  • ESC meeting: -
  • MSAC meeting: -